GSK: A case study

July 08, 2014 | BY

clpstaff &clp articles

GlaxoSmithKline is facing serious charges of misconduct as enforcement grows fierce. The entwining Chinese anti-bribery laws, the US FCPA and UK Bribery Act call for immediate attention to risks and compliance on both a national and global scale

Share:

The Chinese government has substantially beefed up its anti-corruption enforcement in recent years, resulting in arrests and trials of high-level state officials and prominent executives of state-owned entities (SOEs) as